Acuva UV LED…World’s Most Compact, Energy Efficient & Powerful Water Disinfection Module for OEM Appliance Integration
VANCOUVER, British Columbia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Acuva Technologies, a global leader in UVC-LED drinking water disinfection technology, has launched Strike, a platform of compact customizable modules designed specifically for integration into OEM appliances. Acuva’s globally patented UVC-LED disinfection technology is the most precise, reliable and consistent water disinfection system available. Strike’s stainless-steel module design is robust, economical, requires no maintenance, and is mercury-free.
Acuva’s Strike modules are designed to create a controlled optical environment that matches water velocity with UV irradiance to optimize microbial disinfection. Acuva’s innovative technology maximizes available UVC-LED power through optical lensing to deliver an intense collimated beam of UV energy directly into water, while reducing energy consumption and extending LED life with automatic on/off activation.
The slim and compact form-factor of Acuva’s Strike enables integration into a vast array of consumer and commercial appliances that was simply impossible before. This includes water coolers/dispensers/fountains, beverage dispensers, ice/coffee makers and lab water equipment. Furthermore, Strike’s modular design is easily scalable and offers full customization to meet OEM flow rate and disinfection performance requirements.
Acuva’s intelligent, energy efficient self-cooling system is designed to be virtually maintenance‑free as it contains no moving parts and provides hassle-free uninterrupted usage. Additionally, Acuva’s patented technology prevents mineral scaling and eliminates needs for cleaning and frequent replacement, unlike UV lamps.
Acuva provides comprehensive support through every stage of product integration including appliance integration engineering, testing and end-user support.
Acuva’s mercury-free technology is also compliant with the Minamata Convention, the UN Environmental Programme, whose mandate is to encourage the phasing out of mercury by 2020. Acuva’s superior disinfection performance, plus minimal energy and maintenance requirements, offer an unbeatable value proposition for the appliance industry. The return on investment for Acuva Strike modules are as clear as purified water. For more information about Acuva products, including the new Strike module, please visit www.acuvatech.com.
Link to Product Images: http://bit.ly/AcuvaStrike
For more information, media inquiries or to book an interview please contact:
Toll Free 1-800-980-8810
For business and investment inquiries, please contact:
Manoj Singh, CEO
Acuva Technologies is a global leader in the design and manufacture of UV LED drinking water disinfection technology for OEM appliance integration, as well as complete systems for home, off-grid, marine and recreation vehicle use. For more information visit www.acuvatech.com
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research15.11.2018 22:05 | Pressemelding
LYON, France and CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research. The partnership encompasses NYBC becoming a long-term supplier of donor red blood cells (RBC) to ERYTECH, enabling ERYTECH to diversify and broaden its supply of RBC source materials for the production of eryaspase and future product candidates derived from its proprietary ERYCAPS® platform as the company ramps up clinical development. Specifically for the Phase 3 trial in second-line metastatic pancreatic cancer that recently started enrolling patients in Europe, and the Phase 2 trial in first-line triple negative breast cancer (TNBC), which are both expected to begin enrollment in the United States early in 2019. The partnershi
Zageno Deepens Engagement with Scientists and Vendors through Its Meaningful and Unbiased Rating System for Scientific Products — Scientific Score gets Algorithm Update15.11.2018 15:37 | Pressemelding
Call for Contributions: Zageno’s rating system for scientific products — the Scientific Score — adds a crucial dimension to help research scientists purchase the right material for their experiment. Scientists: share your experimental data and professional experience about products; Life Science Vendors: provide additional product-specific resources and data points to make your products reach the right scientist CAMBRIDGE, Mass. USA and BERLIN, Germany, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., the largest and fastest-growing online marketplace for research materials, today issues an open call for scientists and vendors alike to contribute to the continuous improvement of the Scientific Score. Designed as an unbiased indicator to help purchasing scientists navigate the enormous amount of product information, the Scientific Score is the result of proprietary algorithms calculating and weighing different data points across multiple information formats. Among others, factors like rec
SignalFx Delivers Next Generation of Application Performance Monitoring15.11.2018 15:00 | Pressemelding
The first to enable directed troubleshooting for applications and microservices SAN MATEO, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- SignalFx, the leader in real-time cloud monitoring for infrastructure, microservices, and applications, today unveiled SignalFx Microservices APM™, the industry’s first real-time application performance monitoring solution designed to accelerate troubleshooting for DevOps teams through advanced real-time analytics. Powered by NoSample™ distributed tracing architecture, SignalFx Microservices APM observes every single transaction – not just a small random sample – and reports on every anomaly. With the new Outlier Analyzer™, the most challenging issues can now be pinpointed and resolved with a single click. SignalFx Microservices APM is built on top of SignalFx’s advanced streaming analytics platform for metrics which applies unsurpassed data science in real-time to identify the root cause of critical application problems. Integration with advanced automat
Motiv Ring Expands International Footprint and Delivers Industry-First Sizing Process15.11.2018 15:00 | Pressemelding
The wearable ring lands in 20 new countries and eight new stores, and introduces frictionless sizing method SAN FRANCISCO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Motiv Inc., creators of breakthrough wearable technology, today announced an increase of its product availability through new international availability and a new digital sizing set alternative. Motiv Ring’s international expansion will be through its website MyMotiv.com. Featured countries include: North America (Canada), Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, Latvia, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom, Norway and Switzerland), as well as Japan, Taiwan, Turkey, Australia and New Zealand. Good fit is imperative to great functionality. To date, Motiv Ring users select their sizes after receiving a physical sizing kit in the mail. Releasing in Open Beta , Motiv Ring users will now have the additional option of determining their Motiv size via a
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 201815.11.2018 14:30 | Pressemelding
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry diseases WALTHAM, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York. Members of Minerva’s senior management will be joined by an expert key opinion leader. Discussions will feature the following speakers and topics: Gregory P. Strauss, Ph.D., Assistant Professor; Director: Clinical Affective Neuroscience Laboratory; Director: Georgia Psychiatric Risk Evaluation Program; Depa
New Pancreatic Ductal Adenocarcinoma Research Published in Journal of Visualized Experiments15.11.2018 14:00 | Pressemelding
Paper describes well-established protocols for PDAC orthotopic tumor homograft model development and immunoprofiling SAN DIEGO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently published in the Journal of Visual Experiments the establishment and immunological characterization of PDAC orthotopic tumor homograft models. Pancreatic ductal adenocarcinoma (PDAC) research represents an area of high unmet medical need. PDAC fails to respond to a range of cancer therapies, including immunotherapy, partially due to an abundant tumor microenvironment (TME), that protects tumor cells from treatment. The development of new therapeutic and combination strategies requires highly relevant preclinical models recapitulating the complexity of PDAC tumors including the TME. Transplantable PDAC models, developed by pass
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom